A new cancer treatment that delivers radiation directly to tumors by targeting two key markers simultaneously has been shown ...

Induction chemotherapy followed by IMRT is noninferior to CCRT for locoregionally advanced nasopharyngeal carcinoma, data suggest.

The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine ...

Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an ...

Second-line treatment with tarlatamab improves progression-free survival (PFS) and overall survival (OS) when compared to chemotherapy in patients with small cell lung cancer (SCLC), according to ...

Kadlec Tri-Cities Cancer Center in Kennewick has new equipment to improve radiation cancer treatment and also may help arthritis patients as part of a $6.2 million investment. Kadlec Regional ...

ASCO: Guardant blood test guides breast cancer therapy switches, extending survival in AZ-backed study. By Andrea Park Jun 3, 2025 10:00am. Guardant Health Guardant360 AstraZeneca breast ...

Exercise described as ‘novel, first-in-class’ colon cancer therapy . ByMatthew Shinkle. Fact checked byHeather Biele. Add topic to email alerts Receive an email when new articles are posted on .

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.

We performed a phase 3 trial involving women 18 to 70 years of age with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer or its prevention.

CHICAGO — New data on two studies are bolstering hopes that CAR-T therapy, which uses engineered immune T cells to fight cancer, may be able to overcome one of the most difficult to treat ...

Adding tagitanlimab to treatment with gemcitabine and cisplatin (GP) can improve progression-free survival (PFS) in patients with recurrent or metastatic nasopharyngeal cancer (NPC), according to ...